T1	PROC 31 42	traitements
#1	AnnotatorNotes T1	C0087111
T2	DISO 89 99	exposition
#2	AnnotatorNotes T2	C2905623
T3	CHEM 116 127	natalizumab
#3	AnnotatorNotes T3	C1172734
T4	DISO 168 178	exposition
#4	AnnotatorNotes T4	C2905623
T5	CHEM 213 223	interféron
#5	AnnotatorNotes T5	C0021747
T6	CHEM 233 240	acétate
#6	AnnotatorNotes T6	C0000975
T7	DISO 360 370	exposition
#7	AnnotatorNotes T7	C2905623
T8	CHEM 388 406	immunosuppresseurs
#8	AnnotatorNotes T8	C0021081
T9	LIVB 416 424	patients
#9	AnnotatorNotes T9	C0030705
T10	DISO 438 441	SEP
#10	AnnotatorNotes T10	C0026769
T11	CHEM 469 480	médicaments
#11	AnnotatorNotes T11	C0013227
T12	CHEM 504 515	natalizumab
#12	AnnotatorNotes T12	C1172734
T13	PROC 721 737	essais cliniques
#13	AnnotatorNotes T13	C2603343
T14	PROC 743 753	traitement
#14	AnnotatorNotes T14	C0087111
T15	CHEM 775 786	corticoïdes
#15	AnnotatorNotes T15	C0001617
T16	DISO 863 873	infections
#16	AnnotatorNotes T16	C0021311
T17	CHEM 881 892	natalizumab
#17	AnnotatorNotes T17	C1172734
T18	PHYS 936 945	grossesse
#18	AnnotatorNotes T18	C0032961
T19	PHYS 993 1002	grossesse
#19	AnnotatorNotes T19	C0032961
T20	CHEM 1017 1024	TYSABRI
#20	AnnotatorNotes T20	C1529600
T21	CHEM 1040 1047	TYSABRI
#21	AnnotatorNotes T21	C1529600
T22	CHEM 1086 1093	TYSABRI
#22	AnnotatorNotes T22	C1529600
T23	ANAT 1102 1115	lait maternel
#23	AnnotatorNotes T23	C0026140
T24	ANAT 1102 1106	lait
#24	AnnotatorNotes T24	C0026131
T25	LIVB 1172 1178	animal
#25	AnnotatorNotes T25	C0003062
T26	LIVB 1227 1233	femmes
#26	AnnotatorNotes T26	C0015780
T27	PROC 1234 1242	traitées
#27	AnnotatorNotes T27	C0087111
T28	CHEM 1247 1254	TYSABRI
#28	AnnotatorNotes T28	C1529600
T29	CHEM 1338 1349	natalizumab
#29	AnnotatorNotes T29	C1172734
T30	CHEM 1371 1378	TYSABRI
#30	AnnotatorNotes T30	C1529600
T31	LIVB 1419 1426	patient
#31	AnnotatorNotes T31	C0030705
T32	OBJC 1442 1451	véhicules
#32	AnnotatorNotes T32	C0175845
T33	OBJC 1470 1478	machines
#33	AnnotatorNotes T33	C0336779
T34	PROC 1492 1498	études
#34	AnnotatorNotes T34	C2603343
T35	CHEM 1517 1524	placebo
#35	AnnotatorNotes T35	C1696465
T36	LIVB 1546 1554	patients
#36	AnnotatorNotes T36	C0030705
T37	DISO 1568 1571	SEP
#37	AnnotatorNotes T37	C0026769
T38	PROC 1575 1582	traités
#38	AnnotatorNotes T38	C0087111
T39	CHEM 1587 1598	natalizumab
#39	AnnotatorNotes T39	C1172734
T40	CHEM 1629 1636	placebo
#40	AnnotatorNotes T40	C1696465
T41	DISO 1649 1668	arrêt du traitement
#41	AnnotatorNotes T41	C1699848
T42	PROC 1658 1668	traitement
#42	AnnotatorNotes T42	C0087111
T43	LIVB 1703 1711	patients
#43	AnnotatorNotes T43	C0030705
T44	CHEM 1717 1728	natalizumab
#44	AnnotatorNotes T44	C1172734
T45	CHEM 1731 1738	placebo
#45	AnnotatorNotes T45	C1696465
T46	PROC 1774 1780	études
#46	AnnotatorNotes T46	C2603343
T47	LIVB 1796 1804	patients
#47	AnnotatorNotes T47	C0030705
T48	PROC 1805 1812	traités
#48	AnnotatorNotes T48	C0087111
T49	CHEM 1820 1831	natalizumab
#49	AnnotatorNotes T49	C1172734
T50	DISO 1849 1868	effets indésirables
#50	AnnotatorNotes T50	C0559546
T51	CHEM 1877 1887	médicament
#51	AnnotatorNotes T51	C0013227
T52	CHEM 1890 1897	placebo
#52	AnnotatorNotes T52	C1696465
T53	DISO 1906 1925	effets indésirables
#53	AnnotatorNotes T53	C0559546
T54	CHEM 1934 1944	médicament
#54	AnnotatorNotes T54	C0013227
T55	CHEM 1962 1973	natalizumab
#55	AnnotatorNotes T55	C1172734
T56	CHEM 2030 2037	placebo
#56	AnnotatorNotes T56	C1696465
T57	DISO 2144 2191	Affections musculo-squelettiques et systémiques
#57	AnnotatorNotes T57	C0263660
T58	PROC 2212 2228	études cliniques
#58	AnnotatorNotes T58	C0008972
T59	LIVB 2269 2277	patients
#59	AnnotatorNotes T59	C0030705
T60	DISO 2290 2293	SEP
#60	AnnotatorNotes T60	C0026769
T61	PROC 2318 2327	perfusion
#61	AnnotatorNotes T61	C0031001
T62	DISO 2350 2371	événement indésirable
#62	AnnotatorNotes T62	C0559546
T63	PROC 2393 2402	perfusion
#63	AnnotatorNotes T63	C0031001
T64	LIVB 2511 2519	patients
#64	AnnotatorNotes T64	C0030705
T65	DISO 2520 2529	souffrant
#65	AnnotatorNotes T65	C0857256
T66	DISO 2533 2536	SEP
#66	AnnotatorNotes T66	C0026769
T67	PROC 2537 2544	traités
#67	AnnotatorNotes T67	C0087111
T68	CHEM 2549 2560	natalizumab
#68	AnnotatorNotes T68	C1172734
T69	CHEM 2563 2570	placebo
#69	AnnotatorNotes T69	C1696465
T70	CHEM 2630 2641	natalizumab
#70	AnnotatorNotes T70	C1172734
T71	CHEM 2651 2658	placebo
#71	AnnotatorNotes T71	C1696465
T72	DISO 2674 2698	sensations vertigineuses
#72	AnnotatorNotes T72	C1069915
T73	DISO 2701 2708	nausées
#73	AnnotatorNotes T73	C0027497
T74	DISO 2711 2720	urticaire
#74	AnnotatorNotes T74	C0042109
T75	DISO 2724 2732	frissons
#75	AnnotatorNotes T75	C0036973
T76	PROC 2750 2766	études cliniques
#76	AnnotatorNotes T76	C0008972
T77	LIVB 2807 2815	patients
#77	AnnotatorNotes T77	C0030705
T78	DISO 2828 2831	SEP
#78	AnnotatorNotes T78	C0026769
T79	DISO 2852 2868	hypersensibilité
#79	AnnotatorNotes T79	C0020517
T80	LIVB 2897 2905	patients
#80	AnnotatorNotes T80	C0030705
T81	CHEM 2914 2923	anticorps
#81	AnnotatorNotes T81	C0003241
T82	CHEM 2931 2942	natalizumab
#82	AnnotatorNotes T82	C1172734
T83	LIVB 2973 2981	patients
#83	AnnotatorNotes T83	C0030705
T84	PROC 2995 3001	études
#84	AnnotatorNotes T84	C2603343
T85	LIVB 3042 3050	patients
#85	AnnotatorNotes T85	C0030705
T86	DISO 3063 3066	SEP
#86	AnnotatorNotes T86	C0026769
T87	CHEM 3075 3084	anticorps
#87	AnnotatorNotes T87	C0003241
T88	LIVB 3135 3143	patients
#88	AnnotatorNotes T88	C0030705
T89	CHEM 3164 3173	anticorps
#89	AnnotatorNotes T89	C0003241
T90	CHEM 3250 3257	TYSABRI
#90	AnnotatorNotes T90	C1529600
T91	DISO 3314 3330	hypersensibilité
#91	AnnotatorNotes T91	C0020517
T92	DISO 3346 3355	réactions
#92	AnnotatorNotes T92	C1114821
T93	PROC 3367 3376	perfusion
#93	AnnotatorNotes T93	C0031001
T94	CHEM 3408 3417	anticorps
#94	AnnotatorNotes T94	C0003241
T95	DISO 3445 3453	frissons
#95	AnnotatorNotes T95	C0036973
T96	DISO 3456 3463	nausées
#96	AnnotatorNotes T96	C0027497
T97	DISO 3466 3478	vomissements
#97	AnnotatorNotes T97	C0042963
T98	DISO 3482 3503	bouffées vasomotrices
#98	AnnotatorNotes T98	C0016382
T99	PROC 3564 3574	traitement
#99	AnnotatorNotes T99	C0087111
T100	CHEM 3593 3602	anticorps
#100	AnnotatorNotes T100	C0003241
T101	PROC 3721 3730	perfusion
#101	AnnotatorNotes T101	C0031001
T102	CHEM 3751 3760	anticorps
#102	AnnotatorNotes T102	C0003241
T103	CHEM 3907 3916	anticorps
#103	AnnotatorNotes T103	C0003241
T104	PROC 3974 3984	traitement
#104	AnnotatorNotes T104	C0087111
T105	DISO 4025 4041	hypersensibilité
#105	AnnotatorNotes T105	C0020517
T106	DISO 4049 4058	réactions
#106	AnnotatorNotes T106	C1114821
T107	PROC 4070 4079	perfusion
#107	AnnotatorNotes T107	C0031001
T108	PROC 4115 4125	traitement
#108	AnnotatorNotes T108	C0087111
T109	LIVB 4135 4143	patients
#109	AnnotatorNotes T109	C0030705
T110	CHEM 4157 4166	anticorps
#110	AnnotatorNotes T110	C0003241
T111	DISO 4183 4193	Infections
#111	AnnotatorNotes T111	C0021311
T112	DISO 4206 4210	LEMP
#112	AnnotatorNotes T112	C0023524
T113	DISO 4214 4238	infections opportunistes
#113	AnnotatorNotes T113	C0029118
T114	DISO 4214 4224	infections
#114	AnnotatorNotes T114	C0021311
T115	PROC 4257 4273	études cliniques
#115	AnnotatorNotes T115	C0008972
T116	DISO 4295 4319	infections opportunistes
#116	AnnotatorNotes T116	C0029118
T117	DISO 4295 4305	infections
#117	AnnotatorNotes T117	C0021311
T118	PROC 4377 4393	études cliniques
#118	AnnotatorNotes T118	C0008972
T119	DISO 4412 4422	infections
#119	AnnotatorNotes T119	C0021311
T120	DISO 4423 4434	herpétiques
#120	AnnotatorNotes T120	C0019340
T121	LIVB 4437 4457	virus Varicelle-Zona
#121	AnnotatorNotes T121	C0042338
T122	LIVB 4460 4480	virus Herpès-Simplex
#122	AnnotatorNotes T122	C0319232
T123	LIVB 4460 4465	virus
#123	AnnotatorNotes T123	C0042776
T124	LIVB 4520 4528	patients
#124	AnnotatorNotes T124	C0030705
T125	PROC 4529 4536	traités
#125	AnnotatorNotes T125	C0087111
T126	CHEM 4541 4552	natalizumab
#126	AnnotatorNotes T126	C1172734
T127	LIVB 4566 4574	patients
#127	AnnotatorNotes T127	C0030705
T128	CHEM 4580 4587	placebo
#128	AnnotatorNotes T128	C1696465
T129	DISO 4675 4697	encéphalite herpétique
#129	AnnotatorNotes T129	C0276226
T130	LIVB 4718 4726	patients
#130	AnnotatorNotes T130	C0030705
T131	PROC 4751 4761	traitement
#131	AnnotatorNotes T131	C0087111
T132	CHEM 4766 4777	natalizumab
#132	AnnotatorNotes T132	C1172734
T133	DISO 4791 4801	infections
#133	AnnotatorNotes T133	C0021311
T134	PROC 4840 4850	traitement
#134	AnnotatorNotes T134	C0087111
T135	DISO 4876 4880	LEMP
#135	AnnotatorNotes T135	C0023524
T136	PROC 4912 4928	études cliniques
#136	AnnotatorNotes T136	C0008972
T137	DISO 4939 4959	leucoencéphalopathie
#137	AnnotatorNotes T137	C0270612
T138	DISO 4985 4993	handicap
#138	AnnotatorNotes T138	C0231172
T139	PHYS 5007 5012	décès
#139	AnnotatorNotes T139	C0011065
T140	PROC 5095 5101	études
#140	AnnotatorNotes T140	C2603343
T141	LIVB 5118 5126	patients
#141	AnnotatorNotes T141	C0030705
T142	DISO 5140 5143	SEP
#142	AnnotatorNotes T142	C0026769
T143	PROC 5161 5171	traitement
#143	AnnotatorNotes T143	C0087111
T144	CHEM 5188 5208	interféron bêta - 1a
#144	AnnotatorNotes T144	C0254119
T145	CHEM 5188 5198	interféron
#145	AnnotatorNotes T145	C0021747
T146	PROC 5272 5277	essai
#146	AnnotatorNotes T146	C2603343
T147	DISO 5284 5288	LEMP
#147	AnnotatorNotes T147	C0023524
T148	PHYS 5307 5312	décès
#148	AnnotatorNotes T148	C0011065
T149	LIVB 5334 5341	patient
#149	AnnotatorNotes T149	C0030705
T150	DISO 5356 5372	maladie de Crohn
#150	AnnotatorNotes T150	C0010346
T151	DISO 5356 5363	maladie
#151	AnnotatorNotes T151	C0012634
T152	PROC 5430 5441	traitements
#152	AnnotatorNotes T152	C0013216
T153	CHEM 5442 5460	immunosuppresseurs
#153	AnnotatorNotes T153	C0021081
T154	DISO 5483 5494	lymphopénie
#154	AnnotatorNotes T154	C0024312
T155	DISO 5519 5523	LEMP
#155	AnnotatorNotes T155	C0023524
T156	LIVB 5533 5541	patients
#156	AnnotatorNotes T156	C0030705
T157	CHEM 5553 5560	TYSABRI
#157	AnnotatorNotes T157	C1529600
T158	DISO 5634 5653	troubles hépatiques
#158	AnnotatorNotes T158	C0086565
T159	ANAT 5643 5653	hépatiques
#159	AnnotatorNotes T159	C0023884
T160	CHEM 5692 5710	enzymes hépatiques
#160	AnnotatorNotes T160	C0443764
T161	ANAT 5700 5710	hépatiques
#161	AnnotatorNotes T161	C0023884
T162	DISO 5720 5738	hyperbilirubinémie
#162	AnnotatorNotes T162	C0020433
T163	CHEM 5804 5811	Tysabri
#163	AnnotatorNotes T163	C1529600
T164	ANAT 5976 5987	lymphocytes
#164	AnnotatorNotes T164	C0024264
T165	ANAT 5990 5999	monocytes
#165	AnnotatorNotes T165	C0026473
T166	ANAT 6002 6014	éosinophiles
#166	AnnotatorNotes T166	C0014467
T167	ANAT 6018 6028	basophiles
#167	AnnotatorNotes T167	C0004827
T168	PROC 6041 6052	numérations
#168	AnnotatorNotes T168	C0007584
T169	PROC 6123 6133	traitement
#169	AnnotatorNotes T169	C0087111
T170	CHEM 6138 6145	TYSABRI
#170	AnnotatorNotes T170	C1529600
T171	CHEM 6202 6213	hémoglobine
#171	AnnotatorNotes T171	C0019046
T172	PROC 6537 6551	administration
#172	AnnotatorNotes T172	C3469597
T173	PROC 6261 6272	hématocrite
#173	AnnotatorNotes T173	C0518014
T174	ANAT 6309 6321	érythrocytes
#174	AnnotatorNotes T174	C0014792
T175	DISO 6413 6432	symptômes cliniques
#175	AnnotatorNotes T175	C0037088
T176	DISO 6413 6422	symptômes
#176	AnnotatorNotes T176	C1457887
T177	CHEM 6555 6562	TYSABRI
#177	AnnotatorNotes T177	C1529600
T178	CHEM 6567 6590	Agent immunosuppresseur
#178	AnnotatorNotes T178	C0021081
T179	CHEM 6652 6662	intégrines
#179	AnnotatorNotes T179	C0021701
T180	LIVB 6663 6671	humaines
#180	AnnotatorNotes T180	C0086418
T181	ANAT 6718 6728	leucocytes
#181	AnnotatorNotes T181	C0023516
T182	ANAT 6751 6763	neutrophiles
#182	AnnotatorNotes T182	C0027950
T183	CHEM 6793 6804	natalizumab
#183	AnnotatorNotes T183	C1172734
T184	CHEM 6818 6827	intégrine
#184	AnnotatorNotes T184	C0021701
T185	PHYS 6851 6862	interaction
#185	AnnotatorNotes T185	C0687133
T186	CHEM 6890 6899	récepteur
#186	AnnotatorNotes T186	C0001640
T187	OBJC 6905 6913	molécule
#187	AnnotatorNotes T187	C0567416
T188	CHEM 6914 6922	VCAM - 1
#188	AnnotatorNotes T188	C0078056
T189	CHEM 6925 6960	vascular cell adhesion molecule - 1
#189	AnnotatorNotes T189	C0078056
T190	CHEM 6970 6977	ligands
#190	AnnotatorNotes T190	C0023688
T191	CHEM 6978 6990	ostéopontine
#191	AnnotatorNotes T191	C0069676
T192	CHEM 7034 7046	fibronectine
#192	AnnotatorNotes T192	C0016055
T193	CHEM 7052 7058	CS - 1
#193	AnnotatorNotes T193	C0172284
T194	CHEM 7061 7083	connecting segment - 1
#194	AnnotatorNotes T194	C0172284
T195	CHEM 7092 7103	natalizumab
#195	AnnotatorNotes T195	C1172734
T196	PHYS 7115 7126	interaction
#196	AnnotatorNotes T196	C0687133
T197	CHEM 7168 7178	MadCAM - 1
#197	AnnotatorNotes T197	C1138490
T198	CHEM 7181 7225	mucosal addressin cell adhesion molecule - 1
#198	AnnotatorNotes T198	C1138490
T199	PHYS 7253 7265	interactions
#199	AnnotatorNotes T199	C0687133
T200	ANAT 7309 7331	leucocytes mononucléés
#200	AnnotatorNotes T200	C0023517
T201	ANAT 7309 7319	leucocytes
#201	AnnotatorNotes T201	C0023516
T202	ANAT 7346 7357	endothélium
#202	AnnotatorNotes T202	C0014257
T203	ANAT 7367 7388	tissus parenchymateux
#203	AnnotatorNotes T203	C2986654
T204	ANAT 7367 7373	tissus
#204	AnnotatorNotes T204	C0040300
T205	CHEM 7441 7452	natalizumab
#205	AnnotatorNotes T205	C1172734
T206	PHYS 7484 7508	réactions inflammatoires
#206	AnnotatorNotes T206	C0021368
T207	ANAT 7527 7533	tissus
#207	AnnotatorNotes T207	C0040300
T208	PHYS 7564 7576	interactions
#208	AnnotatorNotes T208	C0687133
T209	ANAT 7581 7591	leucocytes
#209	AnnotatorNotes T209	C0023516
T210	CHEM 7631 7638	ligands
#210	AnnotatorNotes T210	C0023688
T211	ANAT 7647 7670	matrice extracellulaire
#211	AnnotatorNotes T211	C0015350
T212	ANAT 7682 7707	cellules parenchymateuses
#212	AnnotatorNotes T212	C0227525
T213	CHEM 7732 7743	natalizumab
#213	AnnotatorNotes T213	C1172734
T214	PHYS 7776 7798	activité inflammatoire
#214	AnnotatorNotes T214	C0021368
T215	DISO 7813 7820	maladie
#215	AnnotatorNotes T215	C0012634
T216	ANAT 7864 7885	cellules immunitaires
#216	AnnotatorNotes T216	C0312737
T217	ANAT 7895 7901	tissus
#217	AnnotatorNotes T217	C0040300
T218	DISO 7945 7948	SEP
#218	AnnotatorNotes T218	C0026769
T219	DISO 7955 7962	lésions
#219	AnnotatorNotes T219	C0175677
T220	ANAT 7988 8001	lymphocytes T
#220	AnnotatorNotes T220	C0039194
T221	PHYS 8024 8052	barrière hémato-encéphalique
#221	AnnotatorNotes T221	C1305865
T222	PHYS 8055 8058	BHE
#222	AnnotatorNotes T222	C1305865
T223	PROC 145 161	essais cliniques
#223	AnnotatorNotes T223	C0008976
T224	CHEM 233 255	acétate de glatiramère
#224	AnnotatorNotes T224	C0289884
T225	CHEM 244 255	glatiramère
#225	AnnotatorNotes T225	C0717787
T226	PHYS 1270 1278	allaiter
#226	AnnotatorNotes T226	C0006147
T227	LIVB 4437 4442	virus
#227	AnnotatorNotes T227	C0042776
T228	CHEM 7134 7150	intégrine α 4β 7
#228	AnnotatorNotes T228	C0648695
T229	DISO 7895 7916	tissus inflammatoires
#229	AnnotatorNotes T229	C0007642
